ClinicalTrials.Veeva

Menu

Effect of Targeted Temperature Management on Cerebral Autoregulation in Patients With Neurocritical Diseases

C

Central South University

Status

Unknown

Conditions

Ischemic Stroke
Subarachnoid Hemorrhage, Aneurysmal
HIE - Hypoxic - Ischemic Encephalopathy
ICH - Intracerebral Hemorrhage
TBI (Traumatic Brain Injury)
Sepsis

Study type

Observational

Funder types

Other

Identifiers

NCT04728438
202101005

Details and patient eligibility

About

Change and effect of cerebral autoregulation during targeted temperature management in neurocritical patients

Full description

Cerebral autoregulation (CA) is the ability of cerebral vascular system to contract or diastole with the change of perfusion pressure, and to maintain the stability of cerebral blood flow. It has been found that there are different degrees of CA damage in patients with traumatic brain injury, ischemic stroke, hemorrhagic stroke, aneurysmal subarachnoid hemorrhage, ischemic hypoxic encephalopathy and sepsis. At the same time, studies have shown that CA damage or loss is related to brain dysfunction and poor prognosis in patients with neurocritical diseases. Therefore, early assessment and intervention of CA can help identify individuals with high risk of complications and improve outcome.

Targeted temperature management (TTM) is a kind of body temperature management started when the core temperature of patients is higher than 37.5 ℃, including achieve hypothermia (TTMhypo) and maintain normal temperature (TTMnorm). TTMhypo has been widely considered as one of the neuroprotective therapies for a variety of brain diseases and injuries, including ischemic stroke, traumatic brain injury, hypoxic brain injury caused by out-of-hospital cardiac arrest and neonatal hypoxic ischemic encephalopathy. Its neuroprotective effects in reducing brain edema, reducing intracranial pressure, reducing brain metabolism and inhibiting apoptosis have been recognized. However, the existing studies mainly focus on the effect of TTMhypo on the mortality and neurological outcome of patients with severe neurological diseases in ICU. There is no large clinical study on the effect of targeted temperature management (TTM) on cerebral autoregulation in patients with severe neurological diseases. Due to the controversy of TTMhypo on mortality and neurological outcome, this study aime to reduce the patient's core temperature to normal. Patients with severe neurological disorders who still had cerebral autoregulation dysfunction, had fever, and needed to reduce the core temperature to normal. Therefore, the effect of TTMnorm on cerebral autoregulation before and during cooling was observed.The main measures were the THRR, Mx and TOx during cooling.

Enrollment

100 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Aneurysmal subarachnoid hemorrhage (aSAH), Traumatic brain injury (TBI), Acute ischemic stroke (AIS), Intracerebral hemorrhage (ICH), Ischemic hypoxic encephalopathy (HIE), sepsis-associated encephalopathy (SAE) who need to reduce the core temperature to normal.

Exclusion criteria

  • Age < 18 years old;
  • Pregnancy;
  • The temporal window was limited and the image could not be obtained;
  • Patients with bradycardia induced by common carotid artery compression and intolerant of THRT
  • Patients with severe carotid artery disease;
  • Uncorrected severe coagulation disorders and active bleeding;
  • Patients without informed consent;
  • Patients who had been treated with hypothermia before inclusion

Trial contacts and locations

1

Loading...

Central trial contact

Lina Zhang, PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems